As a result, there has been growing interest in attempts to augment the PD-1/PD-L1 blockade or target alternative checkpoints in a bid to further improve on outcomes for our refractory or metastatic HNSCC patients. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.